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Society is rapidly changing and so are many aspects of our daily living. From
the ways we communicate with each other to the goods we consume, the
most striking change we have witnessed in the last decades is the falling of
barriers between apparently diverse parts of society and the merging of
different cultures and points of view. We have called this phenomenon
‘globalization’ and, according to its definition, this is ‘the process by which the
world is becoming increasingly interconnected as a result of massively increased trade
and cultural exchange’. How does globalization manifest in science and
scientific research? The short answer is ‘system biology’ for example the
understanding and analysis of biological phenomena through the lenses of
different and yet complementary disciplines (mathematics combined with
enzymology for instance) [1].
Translating these concepts into the world of pharmacology and drug
discovery, one could say diseases are not just a straight line — one organ/
one cell/one signalling pathway — but rather a spider diagram where dif-
ferent ‘factors and problems’ all converge to a single point. With this in
mind, it would be tempting to say that the benefits of combining different
approaches to achieve an improved and safer pharmacological therapy
should be a no brainer. In this section of Immunomodulation, we have
been inspired by this concept and have explored the link between mind and
body in general — the interconnectedness between emotional states and
the immune system specifically — as a possible venue for an improved
treatment of both immune and emotional disorders. I have named this area
of research Affective Immunology (http://www.affectiveimmunology.com).
Why would the link between emotions and immunity be important for drug
design? And why should pharmacologists, in particular, be investigating this
area of research? The answers to these questions are multiple. First, some
immunomodulatory therapies present serious emotional side effects (in-
creased suicide idealization) [2,3], and others might provide a better thera-
peutic effect when administered with ‘emotional modulators’ (see later) [4].
Second, pharmacological therapies for mood disorders have been shown to
be more effective when co-administered with immunomodulatory drugs in
specific cohorts of patients [5–7].
What are the cellular and molecular mechanisms underlying the connection
between emotions and immunity? We know first of all that the immune
system plays a key role in maintaining the emotional system under check
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Editorial overview D’Acquisto ix[8–10]. Studies in both experimental animals and humans
have shown that a dysfunctional or absent immune sys-
tem causes some emotional disorders including anxiety,
depression, obsessive-compulsive disorders and increased
risk of suicide [11–13]. In mice, the absence of immune
cells causes significant changes in memory and cognition
[14–16] and increases the animal’s constitutive basal level
of anxiety-like behavior [17,18]. These effects are linked
to some mechanisms including the lack of homeostatic
‘patrolling’ exerted by the immune cells into the CNS
through newly discovered lymphatic vessels [19,20].
Studies also suggest that the absence of T cells causes
specific changes in the gene expression profile of the
whole brain, and these have been associated with both
anxiety disorders and neurodegenerative diseases [17].
Similar findings have been reported in humans as patients
with either a deficient immune system (HIV) [21,22] or
those with a hyper activated one (autoimmune diseases)
are known to present a high incidence of emotional
disorders [23–26].
Despite this evidence, the scientific community seems to
be reluctant to appreciate the therapeutic value of these
observations. As Lasselin and colleagues stated in their
article, most people are still surprised to hear that ‘immu-
nity is tuned by one’s emotions, personality and social status’.
Therefore, it might come not as a surprise to know that a
defective immune response could be treated by com-
bined targeting of the emotional and immunological
systems. As the authors suggested, this ‘resistance’ might
be because emotional wellbeing is not well-defined and
hence difficult to quantify. The absence of ‘universal’ and
well-tested animal models for the study of emotional
wellbeing might be another cause. Besides these consid-
erations, I think that the resistance also lays on the fact
that wellbeing is not just about how we feel but also about
how we are, as suggested by the authors and others [27].
This is rather important as it suggests that therapies
tackling ‘how one is’ or in other terms one’s life style
might be potentially useful when combined with standard
immunomodulatory therapies.
Along these lines, a large body of evidence has shown a
direct correlation between life style, oxidative stress and
immune and inflammatory chronic diseases [28–30]. The
article by Samina Salin discusses the role of oxidative stress
in neuroinflammation and the fact that many psychiatric
illnesses are reported to exhibit low plasma concentrations of a
variety of antioxidants including glutathione, vitamin E and
coenzyme Q10. The idea that the combined administration
of immunomodulators and changes in life-style might be
beneficial for the therapy of immune and emotional dis-
orders is indeed fascinating as Chiurchiu and Maccarone
suggested. In their article, the authors focused their atten-
tion on bioactive lipids [31–33] and their dual role in
immunity and emotions. From classical lipids like eicosa-
noids and phospholipids to more recent new entries such aswww.sciencedirect.com specialized pro-resolving lipid mediators, the range of med-
iators that could be pharmacologically exploited for their
dual pharmacological effects on emotional state [34,35] and
immunity [36,37] seems to be growing by the year. Of a
particular note for the topic of this volume, the endocanna-
binoid anandamide is the prototype of lipid mediator that
has remarkable effects on the immune system [38] and is
equally effective in emotional disorders [39,40] as its name
(which means ‘inner bliss’) seems to suggest.
The idea of drugs with a potential double role in the
immune and emotional systems is not entirely new.
Neigh and Ali have provided an interesting overview
of immunomodulatory drugs — from the classical steroid
to the modern biologic against inflammatory cytokines —
that are proven for the treatment of post-traumatic stress
disorders (PTSD). The authors also highlighted that
several drugs used for the treatment of PTSD, including selective
serotonin re-uptake inhibitors (SSRI), have been shown to exert
anti-inflammatory effects on T-lymphocytes, dendritic cells, and
neutrophils.
This simultaneous effect on both the immune and emo-
tional system can also be achieved by co-therapy. In their
article Rosenblat and co-authors describe the efficacy of
co-therapy in the treatment of patients suffering from
bipolar disorders. Similar to what has been found for
PTSD or depression, a wide range of drugs including N-
acetylcysteine, infliximab, pioglitazone, celecoxib, aspirin, and
omega-3 polyunsaturated fatty acids have shown an antide-
pressant effect in bipolar disorders when administered adjunc-
tively to conventional treatments.
Co-therapies have also been particularly useful in the
context of immunomodulatory treatment. Indeed, Kovacs
and co-authors provided an extensive overview of the side
effects on the emotional system of a powerful antiviral
and anticancer drug: interferon-alpha [41]. As stated by
the authors, a staggering 10%–40% of patients receiving
this therapy develop a full depressive disorder syndrome
that can include suicidal ideation, aboulia, lack of motiva-
tion, social withdrawal, guilt, anhedonia, irritability, anxiety,
and crying [42,43]. Luckily, the side effects of this drug
seem to be tapered by the co-treatment with traditional
drugs such as SSRI [44] or novel ones such as a diet rich in
omega-3 polyunsaturated fatty acids [45].
Is there any other approach to co-therapies? As we have
just started to better appreciate the colloquium between
the brain and immune cells, an extra level of control has
been taking the center stage in the scientific arena: the
gut–brain axis or — to be more precise — the gut–brain–
immune system triangle. The colloquium has now been
transformed into colloquia. The discoveries emerging
from this field of research are bewildering, to say the
least [46–48]. As Hayley and colleagues pointed out,
bacterial communities generally present in the gut areCurrent Opinion in Pharmacology 2016, 29:viii–xii
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Figure 1
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Affective Immunology: where immunity and emotions
converge. Tag-cloud analysis of the most common terms used in the
contributions made to this volume of Current Opinion in Pharmacology
dedicated to Immunomodulation. Terms like ‘‘depression’’, ‘‘PTSD’’,
‘‘inflammation’’, ‘‘stress’’ and ‘‘cytokines’’ had the highest score (cited
more than 70 times) and might represent the common feature among
all the topics that have been explored. Terms like ‘‘microglia’’, ‘‘GSH’’
and ‘‘gut’’ were the least used (cited 10 times) and might represent
themes that are developing or are more relevant to specific aspects.sensitive to a variety of challenges, including stressors —
the stressors being of emotional nature (the most famous
‘gut feelings’) or a pathogenic factor for the immune
system. In their view, the gut is the real link between
the brain and the immune system as evidenced by the fact
that the benefits of microbiota-targeting compounds on
mood states could be related to their actions on immune
processes. Prebiotics and pro-biotics are the new classes
of drugs currently under investigation for their use in
immune and psychiatric disorders [49–51].
Where do we move from here? Figure 1 shows a tag cloud
analysis of the most common terms present in all the
contributions to this volume and highlight the ’chal-
lenges’ ahead of us. From my personal perspective, there
are still two most important aspects that need to be
explored. First, the role of emotions and immune cells
as guardian of wellbeing. As Ruslan Medzhitov has
highlighted in his recent reviews [52,53], the state of
homoeostasis of the immune system cannot be just inter-
preted as absence of threats from the external environ-
ment. Emotions like stress or simply having a laugh are
part of daily living, and as Steve Cole and colleagues has
very elegantly shown, they directly steer the immune
system towards specific tasks such as antibacterial de-
fense pathway or antiviral response depending on socialCurrent Opinion in Pharmacology 2016, 29:viii–xii factors such as isolation [54–56]. Unraveling the molecu-
lar mechanisms regulating these events might provide an
immense resource for pharmacologists to identify new
molecules and drugs that can help maintain the host in a
state of immunological equilibrium and possibly a healthy
emotional state.
The other aspect that has not been thoroughly investi-
gated is the contribution of emotional or immunological
systems in controlling the transition between acute and
chronic diseases. Indeed, it could be that the disturbance
in emotional wellbeing is one of the leading causes that
make acute inflammatory response transform into chronic
autoimmune disorders. Similarly, change in the immune
system might constitute the tipping point for a weak
emotional state to become a chronic and morbid mood
condition. The validation of this hypothesis would lead to
an entirely new therapeutic protocol where co-therapy
will be substituted by sequential therapies. Thus, a
patient with high risk of mental disorders will be given
treatment for the mental disorder first and an immuno-
modulatory therapy as a preventative of future flares.
Similarly, patients with autoimmune diseases will be
treated with immunosuppressants during the acute phase
of the disease and then kept under ‘emotional modula-
tors’ as soon as remission comes up.
Clearly, the validity of such protocols will require several
clinical trials before a definite answer can be reached. In
the meantime, I hope that this volume on immunomo-
dulation will convince my pharmacologist colleagues as
well as scientists from other disciplines to ‘open their
mind’ and wonder if the disease they are studying could
also be looked at from the perspective of an apparently
distant area of research. As history and current events
have convincingly shown ‘separation’ is never the best
and most convenient choice to address a problem. In life
as in science!
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